Clinical trials: Medication Administration
Dravet Syndrome
Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet Syndrome
This Phase 3 study will enroll participants diagnosed with Dravet Syndrome (DS) who are still experiencing at least one tonic-clonic, clonic, and/or focal seizures with motor components (FSMC) per week, despite ongoing treatment…
- Trial name
- NCT02318563
- Testing
- Cannabidiol Oral Solution
- Sponsor
- INSYS Therapeutics Inc
Uncontrolled Type 2 Diabetes Mellitus
Effect of CPL-2009-0031 in the Treatment of Patients With Uncontrolled Type 2 Diabetes Mellitus
This trial is a Phase-III, Prospective, Randomized, Double Blind, Parallel Group, Two arm, Comparative, Multicenter, controlled clinical trial to determine the efficacy, safety, and tolerability of oral CPL-2009-0031 140 mg in…
- Trial name
- NCT04801199
- Testing
- CPL-2009-0031 140 mg, Sitagliptin 100mg
- Where
- 12 sites in India
- Volunteers
- 355 people
- Sponsor
- Cadila Pharnmaceuticals
Healthy
Bioequivalence Study of Torrent Pharmaceuticals Ltd's Alfuzosin ER Tablets Under Fed Conditions
Objective: Primary objective of the present study was to assess the relative bioavailability of two formulations of Extended Release Alfuzosin 10 mg under Fed conditions, in healthy adult male subjects after an oral…
- Trial name
- NCT01418599
- Testing
- Torrent's Alfuzosin Extended Release Tablet
- Where
- India
- Sponsor
- Torrent Pharmaceuticals Limited
Femoral Arterial Stenosis, Stenosis of Popliteal Arteries
LEVANT Japan Clinical Trial
To demonstrate the safety and efficacy of MD02-LDCB for treatment of stenosis or occlusion of the femoral and popliteal arteries in the Japanese population.
- Conditions
- Femoral Arterial Stenosis, Stenosis of Popliteal Arteries, Femoral Artery Occlusion, Occlusion of Popliteal Arteries
- Trial name
- NCT01816412
- Testing
- MD02-LDCB Paclitaxel coated balloon catheter, Standard Uncoated Balloon Angioplasty Catheter
- Where
- Japan
- Volunteers
- 110 people
- Sponsor
- C. R. Bard
Opioid Use Disorder, Opioid Withdrawal
Medically Supervised Ibogaine With 12-Month Digital Recovery Support for Opioid Use Disorder
IBO-CARE is a single-site Phase 1/2a study evaluating the safety, tolerability, feasibility and preliminary outcomes of medically supervised ibogaine with 12 months of recovery support in adults with moderate-to-severe opioid use…
- Conditions
- Opioid Use Disorder, Opioid Withdrawal, Substance Use Disorders
- Trial name
- IBO-CARE (NCT07871877)
- Testing
- Ibogaine Hydrochloride, Extended-release naltrexone injection, 380 mg, My-E-Health SENTINEL Digital Monitoring and Human-Gated Escalation Platform
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Clive Michelsen
Keratosis
Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands
The purpose of this study is to evaluate the safety and efficacy of imiquimod 5% cream compared to vehicle cream in the treatment of Actinic Keratosis (AK) on the arm and/or hand when the cream is applied once daily 2 days per…
- Trial name
- NCT00115154
- Testing
- Aldara (imiquimod) cream, 5%
- Where
- 18 sites in United States
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- Graceway Pharmaceuticals, LLC
Parkinson's Disease (PD)
A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)
The primary objective of this study was to examine the effect of levodopa-carbidopa intestinal gel (LCIG) compared with optimized medical treatment (OMT) on dyskinesia in participants with advanced Parkinson's disease (PD).
- Trial name
- DYSCOVER (NCT02799381)
- Testing
- Optimized antiparkinsonian treatment, Levodopa-Carbidopa Intestinal Gel (LCIG), CADD-Legacy ambulatory infusion pump
- Where
- 28 sites in United States, Finland and 5 more
- Volunteers
- 63 people
- Sponsor
- AbbVie
Advanced Malignant Tumor
Phase I Clinical Study of HRS-2189 in the Treatment of Patients With Advanced Malignant Tumors
This study is a multi center, open label, dose increasing/dose expanding/efficacy expanding phase I clinical trial aimed at evaluating the safety, tolerance, PK characteristics, and anti-tumor efficacy characteristics of HRS-2189…
- Trial name
- NCT05851092
- Testing
- HRS-2189 Tablets
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Rheumatoid Arthritis
Effect of Patient Cost Sharing on Treatment Discontinuation Among Rheumatoid Arthritis Patients
The purpose of this study is to assess the impact of patient cost sharing on treatment discontinuation of biologic agents in patients with Rheumatoid Arthritis (RA)
- Trial name
- NCT01137851
- Volunteers
- 3,940 people
- Sponsor
- Bristol-Myers Squibb
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
This study will test an experimental drug (enfortumab vedotin) alone and with different combinations of anticancer therapies. Pembrolizumab is an immune checkpoint inhibitor (CPI) that is used to treat patients with cancer of the…
- Conditions
- Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms, Renal Pelvis Neoplasms
- Trial name
- EV-103 (NCT03288545)
- Testing
- enfortumab vedotin (EV), pembrolizumab, cisplatin
- Where
- 106 sites in United States, Canada and 4 more
- Volunteers
- 348 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Chronic Kidney Diseases, Acute Kidney Injury
Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression
Chronic kidney disease CKD is estimated to affect nearly over 800 million people globally today (with roughly 125,000 people ending up annually on dialysis in the United States alone.
- Conditions
- Chronic Kidney Diseases, Acute Kidney Injury, Kidney Failure
- Trial name
- NAD agent (NCT06866236)
- Testing
- QRX-3
- Where
- United States
- Volunteers
- 3,000 people
- Sponsor
- Ebima Clifford Okundaye
Plaque Psoriasis
Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis
The purpose of this study is to establish proof of efficacy for namilumab in moderate to severe plaque psoriasis, measured as Psoriasis Area and Severity Index (PASI)75 response rate at Week 12.
- Trial name
- NCT02129777
- Testing
- Namilumab
- Where
- 10 sites in Canada
- Volunteers
- 122 people
- Sponsor
- Takeda
Type 2 Diabetes Mellitus
Drug-drug Interaction Study(CKD-501, Amlodipine)
The purpose of this study is to assess the pharmacokinetic drug interaction between CKD-501 and amlodipine after oral administration in healthy male volunteers.
- Trial name
- NCT01341392
- Testing
- CKD-501, amlodiopine, CKD-501 amlodipine
- Where
- South Korea
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Diabetes Mellitus
Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.
The purpose of this study is to determine the efficacy of pioglitazone, twice daily (BID), combined with metformin versus pioglitazone taken alone and metformin taken alone in treating Type 2 Diabetes Mellitus.
- Trial name
- NCT00727857
- Testing
- Pioglitazone and metformin, Pioglitazone, Metformin
- Where
- 77 sites in United States, Chile and 2 more
- Volunteers
- 600 people
- Sponsor
- Takeda
Asthma
Cross-Over Study of Subcutaneous Study Drug for the Treatment of Patients With Mild to Moderate Asthma
The objective of this study is to evaluate if single subcutaneous (SC) doses of PL-3994, administered to patients with asthma can achieve a clinically meaningful increase in pulmonary function (Forced Expiratory Volume in one…
- Trial name
- NCT01304628
- Testing
- PL-3994
- Where
- United States
- Sponsor
- Palatin Technologies, Inc
Short Bowel Syndrome, Short Gut Syndrome
A Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Investigational Product MP-101 in Subjects With Short Bowel Syndrome Who Have Had an Inadequate Response to Anti-Diarrheals
MP-101 will be evaluated in this study to see if it is safe, tolerable, and can help people with Short Bowel Syndrome. This study will also find out if taking MP-101 can improve the symptoms of Short Bowel Syndrome and reduce the…
- Conditions
- Short Bowel Syndrome, Short Gut Syndrome, SBS, Short Bowel
- Trial name
- NCT02242656
- Testing
- Opium Tincture USP Deodorized
- Where
- 5 sites in United States
- Sponsor
- Marathon Pharmaceuticals, LLC
Hyperkalemia
Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)
The purpose of this study is to assess the effects of patiromer compared with placebo on serum K+ in HF patients.
- Trial name
- DIAMOND (NCT03888066)
- Testing
- Patiromer
- Where
- 415 sites in United States, Argentina and 19 more
- Volunteers
- 1,195 people
- Sponsor
- Vifor Pharma, Inc.
Healthy
Bioequivalence Study of Pantoprazole Sodium 40 mg Delayed Release Tablets Fasting Study
This study was to compare the single-dose oral bioequivalence of Pantoprazole sodium 40 mg delayed release tablets (containing 45.1 mg of Pantoprazole sodium sesquihydrate equivalent to 40 mg of Pantoprazole) of OHM Laboratories…
- Trial name
- NCT01654705
- Testing
- Pantoprazole
- Where
- India
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Ranbaxy Laboratories Limited
HIV Infections
A Comparison of Two Triple-Drug Combinations in Patients Who Have Never Been Treated With Anti-HIV Drugs
The purpose of this study is to compare the safety of didanosine plus stavudine plus nelfinavir (NLF) with that of zidovudine plus lamivudine plus NLF.
- Trial name
- NCT00002411
- Testing
- Nelfinavir mesylate, Lamivudine, Stavudine
- Where
- 32 sites in United States
- Sponsor
- Bristol-Myers Squibb
Breast Cancer, Metastatic Bone Disease
A Study to Examine the Effects of an Experimental Drug on Women With Breast Cancer and Metastatic Bone Disease (MBD)(0822-016)(COMPLETED)
This is a 4-week study to examine the effects of a new experimental medication on women with breast cancer and established bone metastases. This study will enroll approximately 45 women.
- Trial name
- NCT00399802
- Testing
- ZA, Odanacatib
- Volunteers
- 43 people
- Sponsor
- Merck Sharp & Dohme LLC